Normothermic ex vivo liver machine perfusion (NEVLP) has been developed to address organ shortage in liver transplantation. To establish new therapeutic concepts for the expansion of the donor pool, standardized animal models are needed, that simulate clinical NEVLP. Rat liver grafts were perfused in a dual-vessel NEVLP system using varying doses of the clinically used vasodilator epoprostenol, with and without the addition of the Kupffer cell inhibitor glycine. Cell culture medium supplemented with rat plasma was compared to SteenTM-based perfusion solution, which is used in clinical NEVLP. Perfusion pressures and bile production were recorded, perfusate transaminases levels were measured and tissue was analyzed for cytokines and 8-Isoprostane. Increasing levels of epoprostenol and the addition of glycine resulted in a stepwise decrease of transaminase secretion and improved bile production. SteenTM significantly decreased transaminase secretion as well as IL-1β production, resulting in lowest levels of oxidative stress and best-preserved liver integrity. In conclusion, high doses of epoprostenol seem to ameliorate liver function and prevent cellular damage, with glycine acting synergistically. SteenTM as perfusion basis seems superior. Our rodent NEVLP system may be used to rapidly test new agents for pharmacologic conditioning of livers and to translate these findings from bench-to-bedside.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.